Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis

SIMPLE SUMMARY: The first-line therapy of patients with RAS wild-type (WT) non-resectable metastatic colorectal cancer (mCRC) is usually 5-fluorouracil-based chemotherapy with either bevacizumab or an anti-epidermal growth factor receptor (EGFR). The introduction of anti-epidermal growth factor anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmieri, Lola-Jade, Buchler, Tomas, Meyer, Antoine, Veskrnova, Veronika, Fiala, Ondrej, Brabec, Petr, Baranova, Jana, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946276/
https://www.ncbi.nlm.nih.gov/pubmed/35326562
http://dx.doi.org/10.3390/cancers14061410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946276/
https://www.ncbi.nlm.nih.gov/pubmed/35326562
http://dx.doi.org/10.3390/cancers14061410

Ejemplares similares